Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive disease characterized by its metastatic potential and chemoresistance. These traits are partially attributable to the highly tumorigenic pancreatic cancer stem cells (PaCSCs). Interestingly, these cells show unique features in order...
Main Authors: | Beatriz Parejo-Alonso, Alba Royo-García, Pilar Espiau-Romera, Sarah Courtois, Álvaro Curiel-García, Sladjana Zagorac, Isabel Villaoslada, Kenneth P. Olive, Christopher Heeschen, Patricia Sancho |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-02-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332222015517 |
Similar Items
-
A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC
by: Josephina Sampson, et al.
Published: (2022-02-01) -
Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01) -
Tumor Microenvironment Features and Chemoresistance in Pancreatic Ductal Adenocarcinoma: Insights into Targeting Physicochemical Barriers and Metabolism as Therapeutic Approaches
by: Tiago M. A. Carvalho, et al.
Published: (2021-12-01) -
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
by: Kostas Palamaris, et al.
Published: (2021-11-01) -
TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
by: Andrew Xiao, et al.
Published: (2023-05-01)